News and Press Releases
Press releases
Theralase® Announces Brokered LIFE Financing
Press ReleaseToronto, Ontario – October 23, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or r...
Theralase® Provides Update on Bladder Cancer Clinical Study
Press ReleaseTheralase®’s Latest Clinical Data Demonstrates 65% of Patients Treated with Theralase®’s Anti-Cancer Therapy Achieved a Complete Response Toronto, Ontario – October 16, 2023, Theralase® Technologies Inc. (“Theralase®” or th...
Theralase® Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar™
Press ReleaseToronto, Ontario – September 29, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of li...
Theralase® Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
Press ReleaseToronto, Ontario – September 27, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of li...
Theralase® Grants Stock Options
Press ReleaseToronto, Ontario – September 21, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activa...
Theralase Release’s 2Q2023 Interim Financial Statements
Press ReleaseToronto, Ontario – August 29th, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activ...
Theralase® Announces Appointment of New Independent Director
Press ReleaseToronto, Ontario – June 6, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Phot...
Theralase® Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
Press ReleaseIn the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this press release. Toronto, Ontario – May 30 2023, Theralase® Technologies Inc. (“Theralase...
Theralase® Appoints Roger DuMoulin-White as President and Chief Executive Officer
Press ReleaseToronto, Ontario – May 24, 2023,Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo...
Theralase® Provides Update on Phase II Bladder Cancer Study
Press ReleaseFor the primary objective, 65% of Evaluable Patients (Patients evaluated by a Principal Investigator (“PI”)) achieved a Complete Response (“CR”) at any assessment date post primary Study Treatment and 30% of Evaluable Patients ac...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
